CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 3, 2012
Result type: Reports
Project Number: SR0283-000
Product Line: Reimbursement Review

Generic Name: Tolvaptan

Brand Name: Samsca

Manufacturer: Otsuka Canada Pharmaceutical Inc.

Therapeutic Area: Hyponatremia, non-hypovolemic

Indications: Hyponatremia, non-hypovolemic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 13, 2013

Recommendation Type: Do not list